Centauri Therapeutics, an immunotherapy startup with a proprietary platform technology applicable across a wide range of therapeutic indications, has secured £6 million in further funding from AMR Action Fund, extending its Series A round to £30 million. The investment will support the completion of Phase I clinical studies for CTX-187, the lead clinical candidate in the ABX-01 programme, and expand additional research activities in preparation for Phase II.
The funding will enable advancement of CTX-187 through a Phase I clinical trial to obtain key safety data necessary to inform ongoing development, as well as further work in preparation for Phase II studies. CTX-187, selected as the first clinical candidate in 2025, is built on the Alphamer platform and is designed as a broad-spectrum antimicrobial to treat clinically prevalent and multidrug-resistant Gram-negative bacteria. The compound combines immunotherapeutic effects through complement activation and opsonophagocytosis with intrinsic antibacterial activity, expanding treatment options for vulnerable patients.
In addition, Dr. Henni-Karoliina Ropponen, Venture Associate at AMR Action Fund, has been appointed to Centauri’s Board of Directors.
We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support.
The growing burden of drug-resistant Gram-negative infections is one of the most pressing challenges in global health, leaving patients with limited and increasingly ineffective treatment options. Centauri’s approach represents a promising opportunity to address this challenge, and we are pleased to support the team as they advance toward first-in-human studies.
